Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Combination immune checkpoint blockade as an effective therapy for mesothelioma.

Fear VS, Tilsed C, Chee J, Forbes CA, Casey T, Solin JN, Lansley SM, Joost Lesterhuis W, Dick IM, Nowak AK, Robinson BW, Lake RA, Fisher SA.

Oncoimmunology. 2018 Jul 30;7(10):e1494111. doi: 10.1080/2162402X.2018.1494111. eCollection 2018.

PMID:
30288361
2.

Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma.

Sneddon S, Patch AM, Dick IM, Kazakoff S, Pearson JV, Waddell N, Allcock RJN, Holt RA, Robinson BWS, Creaney J.

BMC Cancer. 2017 Jun 2;17(1):396. doi: 10.1186/s12885-017-3382-6.

3.

A Proteomic Analysis of the Malignant Mesothelioma Secretome Using iTRAQ.

Creaney J, Dick IM, Leon JS, Robinson BW.

Cancer Genomics Proteomics. 2017 Mar-Apr;14(2):103-117.

4.

Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo.

Greening DW, Ji H, Chen M, Robinson BW, Dick IM, Creaney J, Simpson RJ.

Sci Rep. 2016 Sep 8;6:32643. doi: 10.1038/srep32643.

5.

Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers.

Creaney J, Dick IM, Musk AW, Olsen NJ, Robinson BW.

Biomarkers. 2016 Sep;21(6):551-61. doi: 10.3109/1354750X.2016.1160429. Epub 2016 Mar 24.

PMID:
27009350
6.

Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma.

Robinson C, Dick IM, Wise MJ, Holloway A, Diyagama D, Robinson BW, Creaney J, Lake RA.

BMC Cancer. 2015 Dec 18;15:983. doi: 10.1186/s12885-015-1953-y.

7.

Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations.

Lesterhuis WJ, Rinaldi C, Jones A, Rozali EN, Dick IM, Khong A, Boon L, Robinson BW, Nowak AK, Bosco A, Lake RA.

Sci Rep. 2015 Jul 21;5:12298. doi: 10.1038/srep12298.

8.

Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen.

Creaney J, Ma S, Sneddon SA, Tourigny MR, Dick IM, Leon JS, Khong A, Fisher SA, Lake RA, Lesterhuis WJ, Nowak AK, Leary S, Watson MW, Robinson BW.

Oncoimmunology. 2015 May 11;4(7):e1011492. eCollection 2015 Jul.

9.

Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma.

Creaney J, Dick IM, Robinson BW.

Curr Opin Pulm Med. 2015 Jul;21(4):352-6. doi: 10.1097/MCP.0000000000000167. Review.

PMID:
26016578
10.

Discovery of new biomarkers for malignant mesothelioma.

Creaney J, Dick IM, Robinson BW.

Curr Pulmonol Rep. 2015;4(1):15-21. Review.

11.

Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma.

Sneddon S, Leon JS, Dick IM, Cadby G, Olsen N, Brims F, Allcock RJ, Moses EK, Melton PE, de Klerk N, Musk AW, Robinson BW, Creaney J.

Gene. 2015 May 25;563(1):103-5. doi: 10.1016/j.gene.2015.03.031. Epub 2015 Mar 18.

12.

Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma.

Creaney J, Segal A, Olsen N, Dick IM, Musk AW, Skates SJ, Robinson BW.

Dis Markers. 2014;2014:413946. doi: 10.1155/2014/413946. Epub 2014 Nov 23.

13.

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.

Creaney J, Dick IM, Meniawy TM, Leong SL, Leon JS, Demelker Y, Segal A, Musk AW, Lee YC, Skates SJ, Nowak AK, Robinson BW.

Thorax. 2014 Oct;69(10):895-902. doi: 10.1136/thoraxjnl-2014-205205. Epub 2014 Jul 18.

14.

Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum.

Creaney J, Sneddon S, Dick IM, Dare H, Boudville N, Musk AW, Skates SJ, Robinson BW.

Dis Markers. 2013;35(2):119-27. doi: 10.1155/2013/874212. Epub 2013 Aug 6.

15.

Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma.

Creaney J, Dick IM, Segal A, Musk AW, Robinson BW.

Lung Cancer. 2013 Dec;82(3):491-8. doi: 10.1016/j.lungcan.2013.09.016. Epub 2013 Oct 9.

PMID:
24161718
16.

Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity.

Lesterhuis WJ, Salmons J, Nowak AK, Rozali EN, Khong A, Dick IM, Harken JA, Robinson BW, Lake RA.

PLoS One. 2013 Apr 23;8(4):e61895. doi: 10.1371/journal.pone.0061895. Print 2013.

17.

Does CA125 binding to mesothelin impact the detection of malignant mesothelioma?

Creaney J, Dick IM, Dare H, Demelker Y, Nowak AK, Musk AW, Robinson BW.

Lung Cancer. 2013 Apr;80(1):39-44. doi: 10.1016/j.lungcan.2012.12.008. Epub 2013 Jan 26.

PMID:
23357461
18.

Peripheral CD8(+) T cell proliferation is prognostic for patients with advanced thoracic malignancies.

McCoy MJ, Nowak AK, van der Most RG, Dick IM, Lake RA.

Cancer Immunol Immunother. 2013 Mar;62(3):529-39. doi: 10.1007/s00262-012-1360-z. Epub 2012 Oct 16.

19.

Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies.

McCoy MJ, Lake RA, van der Most RG, Dick IM, Nowak AK.

Br J Cancer. 2012 Sep 25;107(7):1107-15. doi: 10.1038/bjc.2012.362. Epub 2012 Aug 21.

20.

A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma.

Nowak AK, Millward MJ, Creaney J, Francis RJ, Dick IM, Hasani A, van der Schaaf A, Segal A, Musk AW, Byrne MJ.

J Thorac Oncol. 2012 Sep;7(9):1449-56. doi: 10.1097/JTO.0b013e31825f22ee.

21.

Auto-antibodies to β-F1-ATPase and vimentin in malignant mesothelioma.

Creaney J, Dick IM, Yeoman D, Wong S, Robinson BW.

PLoS One. 2011;6(10):e26515. doi: 10.1371/journal.pone.0026515. Epub 2011 Oct 17.

22.

Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden.

Creaney J, Francis RJ, Dick IM, Musk AW, Robinson BW, Byrne MJ, Nowak AK.

Clin Cancer Res. 2011 Mar 1;17(5):1181-9. doi: 10.1158/1078-0432.CCR-10-1929. Epub 2010 Dec 21.

23.

Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma.

Creaney J, Olsen NJ, Brims F, Dick IM, Musk AW, de Klerk NH, Skates SJ, Robinson BW.

Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2238-46. doi: 10.1158/1055-9965.EPI-10-0346. Epub 2010 Jul 22.

24.

In vitro kinetic properties of the Thr201Met variant of human aromatase gene CYP19A1: functional responses to substrate and product inhibition and enzyme inhibitors.

Payne EJ, Ingley E, Dick IM, Wilson SG, Bond CS, Prince RL.

J Clin Endocrinol Metab. 2009 Aug;94(8):2998-3002. doi: 10.1210/jc.2008-2309. Epub 2009 May 26.

PMID:
19470632
25.

Common sequence variation in FLNB regulates bone structure in women in the general population and FLNB mRNA expression in osteoblasts in vitro.

Wilson SG, Jones MR, Mullin BH, Dick IM, Richards JB, Pastinen TM, Grundberg E, Ljunggren O, Surdulescu GL, Dudbridge F, Elliott KS, Cervino AC, Spector TD, Prince RL.

J Bone Miner Res. 2009 Dec;24(12):1989-97. doi: 10.1359/jbmr.090530.

26.

The effects of homocysteine and MTHFR genotype on hip bone loss and fracture risk in elderly women.

Zhu K, Beilby J, Dick IM, Devine A, Soós M, Prince RL.

Osteoporos Int. 2009 Jul;20(7):1183-91. doi: 10.1007/s00198-008-0804-y. Epub 2008 Nov 27.

PMID:
19037576
27.

Identification of a role for the ARHGEF3 gene in postmenopausal osteoporosis.

Mullin BH, Prince RL, Dick IM, Hart DJ, Spector TD, Dudbridge F, Wilson SG.

Am J Hum Genet. 2008 Jun;82(6):1262-9. doi: 10.1016/j.ajhg.2008.04.016. Epub 2008 May 22.

28.

Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women.

Prince RL, Austin N, Devine A, Dick IM, Bruce D, Zhu K.

Arch Intern Med. 2008 Jan 14;168(1):103-8. doi: 10.1001/archinternmed.2007.31.

PMID:
18195202
29.

Chocolate consumption and bone density in older women.

Hodgson JM, Devine A, Burke V, Dick IM, Prince RL.

Am J Clin Nutr. 2008 Jan;87(1):175-80.

PMID:
18175753
30.
31.

Bone structural effects of variation in the TNFRSF1B gene encoding the tumor necrosis factor receptor 2.

Mullin BH, Prince RL, Dick IM, Islam FM, Hart DJ, Spector TD, Devine A, Dudbridge F, Wilson SG.

Osteoporos Int. 2008 Jul;19(7):961-8. Epub 2007 Nov 24.

PMID:
18038243
32.

The importance of calculating absolute rather than relative fracture risk.

Tucker G, Metcalfe A, Pearce C, Need AG, Dick IM, Prince RL, Nordin BE.

Bone. 2007 Dec;41(6):937-41. Epub 2007 Aug 3. Erratum in: Bone. 2008 Jun;42(6):1241.

PMID:
17942381
33.

Tea drinking is associated with benefits on bone density in older women.

Devine A, Hodgson JM, Dick IM, Prince RL.

Am J Clin Nutr. 2007 Oct;86(4):1243-7.

PMID:
17921409
34.

Association of back pain frequency with mortality, coronary heart events, mobility, and quality of life in elderly women.

Zhu K, Devine A, Dick IM, Prince RL.

Spine (Phila Pa 1976). 2007 Aug 15;32(18):2012-8.

PMID:
17700450
35.
36.

The clinical utility of measured kyphosis as a predictor of the presence of vertebral deformities.

Prince RL, Devine A, Dick IM.

Osteoporos Int. 2007 May;18(5):621-7. Epub 2006 Dec 2.

PMID:
17143655
37.

No associations between OPG gene polymorphisms or serum levels and measures of osteoporosis in elderly Australian women.

Ueland T, Bollerslev J, Wilson SG, Dick IM, Islam FM, Mullin BH, Devine A, Prince RL.

Bone. 2007 Jan;40(1):175-81. Epub 2006 Sep 1.

PMID:
16949901
38.
39.

Klotho gene polymorphisms are associated with osteocalcin levels but not bone density of aged postmenopausal women.

Mullin BH, Wilson SG, Islam FM, Calautti M, Dick IM, Devine A, Prince RL.

Calcif Tissue Int. 2005 Sep;77(3):145-51. Epub 2005 Sep 8.

PMID:
16151675
40.

Protein consumption is an important predictor of lower limb bone mass in elderly women.

Devine A, Dick IM, Islam AF, Dhaliwal SS, Prince RL.

Am J Clin Nutr. 2005 Jun;81(6):1423-8.

PMID:
15941897
41.

LRP5 gene polymorphisms predict bone mass and incident fractures in elderly Australian women.

Bollerslev J, Wilson SG, Dick IM, Islam FM, Ueland T, Palmer L, Devine A, Prince RL.

Bone. 2005 Apr;36(4):599-606.

PMID:
15777745
42.

Bone mass effects of a BMP4 gene polymorphism in postmenopausal women.

Ramesh Babu L, Wilson SG, Dick IM, Islam FM, Devine A, Prince RL.

Bone. 2005 Mar;36(3):555-61.

PMID:
15777683
43.

Association of an aromatase TTTA repeat polymorphism with circulating estrogen, bone structure, and biochemistry in older women.

Dick IM, Devine A, Prince RL.

Am J Physiol Endocrinol Metab. 2005 May;288(5):E989-95. Epub 2004 Dec 21.

44.

Effects of endogenous estrogen on renal calcium and phosphate handling in elderly women.

Dick IM, Devine A, Beilby J, Prince RL.

Am J Physiol Endocrinol Metab. 2005 Feb;288(2):E430-5. Epub 2004 Oct 5.

45.

Physical activity and calcium consumption are important determinants of lower limb bone mass in older women.

Devine A, Dhaliwal SS, Dick IM, Bollerslev J, Prince RL.

J Bone Miner Res. 2004 Oct;19(10):1634-9. Epub 2004 Aug 3.

46.

Prediction of incident osteoporotic fractures in elderly women using the free estradiol index.

Devine A, Dick IM, Dhaliwal SS, Naheed R, Beilby J, Prince RL.

Osteoporos Int. 2005 Feb;16(2):216-21. Epub 2004 Jun 10.

PMID:
15197544
47.

Prevalence of lower extremity pain and its association with functionality and quality of life in elderly women in Australia.

Chen J, Devine A, Dick IM, Dhaliwal SS, Prince RL.

J Rheumatol. 2003 Dec;30(12):2689-93.

PMID:
14719214
48.

Estrogen and androgen regulation of plasma membrane calcium pump activity in immortalized distal tubule kidney cells.

Dick IM, Liu J, Glendenning P, Prince RL.

Mol Cell Endocrinol. 2003 Dec 30;212(1-2):11-8.

PMID:
14654246
49.

Calcium-sensing receptor gene polymorphism A986S does not predict serum calcium level, bone mineral density, calcaneal ultrasound indices, or fracture rate in a large cohort of elderly women.

Bollerslev J, Wilson SG, Dick IM, Devine A, Dhaliwal SS, Prince RL.

Calcif Tissue Int. 2004 Jan;74(1):12-7. Epub 2003 Sep 29.

PMID:
14508624
50.

Supplemental Content

Support Center